TFS HealthScience (TFS), a global contract research organization (CRO), announced the appointment of long-standing member of the company, Miriam Martin , as Vice President of Business Development, Clinical Development Services (CDS). With this new role, Miriam will also join the TFS Executive Committee, reinforcing the company's commitment to strategic growth, operational excellence, and fostering strong partnerships.
Miriam has been a pillar of TFS for over 15 years, making significant contributions to the company's financial success through her leadership roles with increasing responsibilities and her in-depth industry knowledge, which extends to both sponsors and CROs. Her leadership marks an era of transformation at TFS, encompassing five acquisitions, the integration into the Ratos Group , and the company's global expansion into key regions in North America, Europe, the Asia-Pacific region, and the Middle East. Over the past five years, Miriam has delivered compelling sales performance and driven growth in key business development functions. Under her leadership, she has also increased the scalability and success of TFS's Functional Service Provider (FSP) model, enabling flexible, high-quality strategic resourcing solutions tailored to partners' evolving needs.
"Miriam's impact on TFS is both profound and lasting," explains Markus Granlund , CEO of TFS HealthScience. "She has played a key role in shaping TFS as we know it today. Her leadership, insight, and tireless commitment to our company and our mission make her the ideal fit for this position. We are proud to welcome her to the Executive Committee."
Miriam's appointment comes at a time when TFS is experiencing continued momentum, underscored by advances in the company's key therapeutic areas. Most recently, the company initiated pivotal early- and late-phase clinical programs in ophthalmology, including studies in diabetic macular edema and other retinal diseases, and expanded its oncology efforts in pancreatic cancer, non-small cell lung cancer, and other hematology indications. TFS is also expanding its portfolios in dermatology and neuroscience, recently awarding studies in atopic dermatitis, complex wound healing, and multiple sclerosis. This progress underscores the company's extensive therapeutic expertise and unwavering commitment to scientific excellence and patient-centered impact.
"I'm deeply honored to continue growing with TFS in this role," explains Miriam Martin . "TFS has believed in me, invested in me, and surrounded me with remarkable people. I'm grateful to everyone who has supported me and look forward to continuing to work toward our goal of empowering our partners and enriching lives."
As Vice President of Business Development, CDS, Miriam will focus on strengthening client engagement, driving sustainable growth strategies, and driving innovative approaches to clinical development. Her seat on the Executive Committee will provide her with increased opportunities to advocate for TFS's partners, collaborate cross-functionally, and further strengthen an inclusive culture that prioritizes relationships, innovation, and shared success.